Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00856050 · ClinicalTrials.gov registry record · Phase 2
Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
A Phase 2 study of Leiomyosarcoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT00856050 is a Phase 2 study of Leiomyosarcoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 27 participants, below the 120-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00856050, a Phase 2 study of Leiomyosarcoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine if letrozole is effective at controlling the growth or spread of estrogen and/or progesterone receptor positive uterine leiomyosarcoma. This drug has been used in research studies for other cancers and is currently approved by the FDA for use in breast cancer. Because letrozole lowers hormone levels in the body, it may be helpful to control tumors that express hormone receptors ( ER/PR).
Conditions Studied
Interventions
- DRUG letrozole
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-02 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00856050
The ClinicalTrials.gov registry entry for NCT00856050 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 120-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (77% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leiomyosarcoma appearing as the primary indexed condition, and to 1 intervention - of which letrozole is the first listed.
NCT00856050 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00856050 about?
NCT00856050 is a clinical study titled "Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma". The purpose of this research study is to determine if letrozole is effective at controlling the growth or spread of estrogen and/or progesterone receptor positive uterine leiomyosarcoma. This drug has been used in research studies for other cancers and is currently approved by the FDA for use in bre...
What is the current status of trial NCT00856050?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2009-02. Estimated completion is 2014-03.
What conditions does trial NCT00856050 study?
This clinical trial studies the following conditions: Leiomyosarcoma.
What interventions are being tested in trial NCT00856050?
The interventions under investigation include: letrozole (DRUG).
Who is sponsoring clinical trial NCT00856050?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00856050 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
RECRUITING · Phase 2
-
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Nivolumab in Selected Uterine Cancer Patients
COMPLETED · Phase 2
-
Bevacizumab and Radiation Therapy for Sarcomas
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.